An external third party (pharma partner) will be the validation the market needs and could be seen as a measure of the strength of the AA chances from their perspective IMO .... who that partner / global pharma is and for what amount they contribute will be telling (again IMO) ....
..... chances are they have seen more Rexlemestrocel-L data through an NDA than the 'docs' on HC have (lol ) so the size of their financial commitment will IMO be a measure / guidance as to their confidence in a successful FDA AA outcome for this indication ?
GLTAH
MSB Price at posting:
33.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
) so the size of their financial commitment will IMO be a measure / guidance as to their confidence in a successful FDA AA outcome for this indication ?
(20min delay)